Clinical trial · Observational
Evaluation of the Pathobiology of CALR-mutated MPN Cells
NCT06480591CI-TRIAL-00117694recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Draw | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- JAK2 V617F mutation positive MPN patients
- description
- Patients with MPN disease with a JAK2 mutation
- interventionNames
- Other: Blood Draw
- label
- CALR-mutation positive patients
- description
- Patients with MPN disease with a CALR mutation
- interventionNames
- Other: Blood Draw
Primary outcomes (1)
- measure
- Expression levels of TLR 2 and TLR 4
- timeFrame
- 24 months
- description
- Percentages of mononuclear cells expressing TLR 2 and TLR 4 will be calculated for each participant.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR). * Age ≥ 18 years at the time of enrollment * Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs * CALR-positive genetic mutation Exclusion Criteria: \- Diagnosis of MPN with JAK2 V617F mutation
References
Publications (0)
Data not yet available
No reference posted for this study.